Development Services

Lateral Flow Point-of-Care Rapid Test Development

For three decades lateral flow technology has provided patients, clinicians, and employers with rapid, point-of-care testing for a variety of compounds contained in numerous matrices. From the earliest commercial kits used to test for ovulation and pregnancy, to recent approvals allowing for home collection of samples for the early detection of colorectal cancer, lateral flow technology has remained the standard bearer in immunological testing. Predicated on the ability of antibodies to specifically bind analytes as small as traditional drugs and their metabolites, the range of possible targets for development of a lateral flow assay is nearly limitless. ALFA customers, including many of the top 10 global diagnostic companies, benefit from our 20-years of experience in developing world class, rapid lateral flow tests. Utilizing our IVD rapid test development competencies, our in-house science team is ready to tackle new challenges presented by our client’s needs.  Whether for drugs-of-abuse, fertility, or disease screening, no device is beyond ALFA's expertise to design, regardless of testing matrix (e.g. urine, saliva, blood, solubilized solid). Speed and accuracy in testing development are not mutually exclusive at ALFA, with project completion times often 50% faster than our competitors, again delivering on our “Accuracy at the Speed of ALFA” promise.